Clinical trial
Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma…
NCT00054496 · The Cleveland Clinic, Other · Unknown status
Key facts
| NCT number | NCT00054496 |
|---|---|
| Title | Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme |
| Official title | Phase II Study Trial Of Tarceva In Patients With Recurrent/Progressive Glioblastoma Multiforme |
| Lead sponsor | The Cleveland Clinic, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | erlotinib hydrochloride |
| Enrollment | 73 |
| Start date | Aug 1, 2002 |
| First posted | Feb 6, 2003 |
| Last update posted | Jan 10, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: